---
title: "Novo Nordisk A/S - share repurchase programme | NVO Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/305678308.md"
description: "Novo Nordisk announced updates to its share repurchase program. Between November 9 and 13, 2026, the company repurchased approximately 1.1 million B shares at an average price of DKK 275.48, totaling roughly DKK 307 million. As of November 13, Novo Nordisk holds 57.6 million treasury shares (1.3% of capital). Since February 4, 2026, it has repurchased over 43.7 million shares for DKK 12.1 billion, within a DKK 15 billion annual limit."
datetime: "2026-11-16T05:24:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/305678308.md)
  - [en](https://longbridge.com/en/news/305678308.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/305678308.md)
generator: "portal-rs"
---

# Novo Nordisk A/S - share repurchase programme | NVO Stock News

See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google

Add on Google

**Novo Nordisk A/S – Share repurchase programme**

**Bagsværd, Denmark, 16 November 2026** – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 4 February 2026.

Under the programme initiated 6 May 2026, Novo Nordisk will repurchase B shares for an amount up to DKK 11,200,000,010.45 in the period from 6 May 2026 to 1 February 2027.

Since the announcement 9 November, the following transactions have been made:

****Number of****  
****B shares****

****Average****  
****purchase price****

****Transaction****  
****value, DKK****

**Accumulated, last announcement**

**27,845,000**

**8,008,013,722**

9 November 2026

230,000

273.19

62,833,589

10 November 2026

225,000

273.53

61,543,729

11 November 2026

225,000

272.61

61,336,770

12 November 2026

225,000

276.39

62,188,860

13 November 2026

225,000

276.25

62,156,610

**Accumulated under the programme**

**28,975,000**

**8,318,073,280**

The details for each transaction made under the share repurchase programme are published on novonordisk.com.

Transactions related to Novo Nordisk’s incentive programmes have resulted in a net transfer from Novo Nordisk of 129,745 B shares in the period from from 9 November 2026 to 13 November 2026 The shares in these transactions were not part of the Safe Harbour repurchase programme.  
With the transactions stated above, Novo Nordisk owns a total of 57,645,131 B shares of DKK 0.10 as treasury shares, corresponding to 1.3% of the share capital. The total amount of A and B shares in the company is 4,465,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion during a 12-month period beginning 4 February 2026. As of 13 November 2026, Novo Nordisk has since 4 February 2026 repurchased a total 43,734,179 B shares at an average share price of DKK 277.08 per B share equal to a transaction value of DKK 12,118,073,269.

*Novo is the global healthcare company that believes lasting health starts now. For over a century, we’ve combined leading scientific expertise with a deep understanding of people’s lives. We develop treatments and support that help millions of people make progress they can see, feel and sustain now and in the future. Every day, over 66,500 employees around the world advance our purpose to drive change for lasting health.* *Through our partnerships, programmes and investments, we’re working to prevent disease, expand access to treatments and reduce our environmental impact to help even more people live healthier lives. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com and follow us on Instagram, LinkedIn, TikTok, Facebook, X and YouTube.* 

**Contacts for further information**

**Novo Nordisk Media:**

**Ambre James-Brown**  
+45 3079 9289  
globalmedia@novonordisk.com  

**Liz Skrbkova (US)**  
+1 609 917 0632  
USMediaRelations@novonordisk.com  

**Novo Nordisk Investors:**

**Michael Novod**  
+45 3075 6050  
nvno@novonordisk.com  

**Sina Meyer**  
+45 3079 6656  
azey@novonordisk.com  

**Max Ung**  
+45 3077 6414  
mxun@novonordisk.com

**Christoffer Togo Solgaard-Tullin**  
+45 3079 1471  
cftu@novonordisk.com  

**Ida Schaap Melvold**  
+45 3077 5649  
idmg@novonordisk.com  

**Mads Berner Bruun**  
+45 3075 2936  
mbbz@novonordisk.com  

**Frederik Taylor Pitter (US)**  
+1 609 613 0568  
fptr@novonordisk.com  

**Alex Bruce (US)**  
+1 640 230 0276  
axeu@novonordisk.com

Company announcement No 68 / 2026

-   CA20261611\_Safe Harbour
-   CA20261611\_Safe harbour transaction details

### Related Stocks

- [NVO.US](https://longbridge.com/en/quote/NVO.US.md)
- [NVOC.US](https://longbridge.com/en/quote/NVOC.US.md)
- [NVOH.US](https://longbridge.com/en/quote/NVOH.US.md)
- [NVOX.US](https://longbridge.com/en/quote/NVOX.US.md)

## Related News & Research

- [Novo Nordisk announces results from two post hoc analyses of phase 3 Redefine 1](https://longbridge.com/en/news/305582142.md)
- [Novo Nordisk Showcases CagriSema Trial Gains and Wegovy Food Noise Reductions Ahead of FDA Decision](https://longbridge.com/en/news/305698162.md)
- [Novo Nordisk (CPSE:NOVO B) Reports Phase 3 Win In Obesity Trial For Children Under 12](https://longbridge.com/en/news/305854398.md)
- [Novo Nordisk Highlights Protective Bone Biomarkers For CagriSema And Pediatric BMI Drops](https://longbridge.com/en/news/305843862.md)
- [Novo says Wegovy injection lowers BMI and obesity rates in children in trial](https://longbridge.com/en/news/305691906.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**